FDA Launches Council to Overhaul Its Inspections

FDA has set up a new cross-agency body, the Inspectional Affairs Council, to govern how the agency plans, coordinates, and prioritizes facility inspections — and said explicitly, for the first time in one place, that inspection frequency should track a facility’s risk and compliance history rather than a uniform schedule. The announcement came in an FDA Voices post from Elizabeth Miller, the agency’s Associate Commissioner for Inspections and Investigations, and Lowell Zeta, Acting Chief of Staff and Deputy Commissioner for Strategic Initiatives, and it formalizes changes that have been building since May.

What the council actually does

The Inspectional Affairs Council is a coordinating body, not a new inspection unit. Its job, per the FDA Voices post, is to standardize priorities and align FDA’s inspection approach across centers that have historically set their own inspectional strategy with limited cross-agency visibility — drugs, devices, biologics, and the Human Foods Program each running their own playbook. The Office of Inspections and Investigations sits on the council alongside center leadership, giving OII a forum to coordinate strategic decisions rather than negotiate them center by center. The council's authority is formalized in a Staff Manual Guide that took effect in May 2026, which the agency says makes inspectional processes and priorities consistently applied and visible to both internal staff and outside stakeholders — a documentation step that matters because SMGs are the internal procedural backbone FDA staff are expected to follow.

Risk, complexity, and a facility's own record

The substantive change is the explicit shift toward what FDA calls right-sizing: matching inspectional effort to risk, complexity, and public health need rather than applying a roughly uniform cadence across similarly regulated facilities. The agency's own framing is direct — a facility with stable operations and a documented history of voluntary compliance may warrant a lower inspection priority than one with complex manufacturing processes or known compliance concerns. For a quality organization, that reframes inspection readiness as a function of demonstrated track record over time, not just current-state documentation. It also raises the stakes on maintaining a clean compliance history, since the post frames that history as a direct input into how often FDA shows up.

A second, separate reorganization is coming in October

The Inspectional Affairs Council should not be conflated with Simple Reform, the broader administrative reorganization the Trump Administration approved separately and which takes effect 1 October 2026. That plan centralizes functions like human resources, finance, and information technology under FDA's Office of Operations on a shared-service model, and moves specialized field inspectors — who currently focus on specific product categories — toward operating as generalists conducting inspections across multiple industries. FDA officials have pushed back on describing that shift as simply “going generalist,” saying the workforce model is designed to deepen investigator capability and expertise rather than dilute it. The two initiatives share a modernization goal and overlap in practice, but they were approved on different tracks and take effect on different dates — worth keeping straight when reading either announcement.